Recombinant BCG Vaccine developed at Max Planck Institute for Infection Biology, Berlin - new hope for treatment of Tuberculosis

Date: 
Thursday, March 10, 2016

BCG-based Tuberculosis (TB) vaccine, VPM1002, developed by the group of Prof. Stefan H. E. Kauffman, founding director of Max Planck Institute for Infection Biology, Berlin is all set to enter clinical trails at Serum Institute of India Limited in Pune. This vaccine has been already successful in animal and small scale human trails and is expected to potentially target both pulmonary and extra pulmonary forms of TB in children and adults alike.

 

For further reading: http://www.thehindu.com/opinion/op-ed/new-bcgbased-tb-vaccine-revamped-safer-and-with-greater-punch/article8262023.ece?topicpage=true&topicId=2045